Cure8 news brief
Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to treat.
Manufacturing scale-up and regulatory steps are central to whether the therapy can move beyond early use.
Patients with fistulising Crohn’s disease, caregivers, clinicians treating refractory Crohn’s, researchers in cell therapies, and investors following IBD therapeutics development.
This is an investor/earnings event summary describing early clinical experience (special-access / compassionate-use) and the company’s near-term development plans for StemSmart in Crohn’s disease. The 80% response figure refers to five special-access patients and is reported by the company; it is not a peer-reviewed clinical trial publication.
The company plans Phase 2 trials and is completing manufacturing transfer and regulatory interactions. The update also notes business and financial items (cash position, R&D spend) and that an unrelated program (EmtinB for glaucoma) is being moved toward out-licensing.
The safety comment in the summary states no serious adverse events were observed in the five special-access patients.
Reported results are from five special-access patients and come from company investor/earnings materials. They are not a peer-reviewed study report; confirmatory data will depend on the planned Phase 2 trials and regulatory review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Treg cell therapy aims to reduce harmful immune activity that drives Crohn's disease. If developed successfully, it could become a targeted cell-based treatment option for patients who don't respond to current therapies.
This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...
The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters...
